

A panel of four miRNAs (miR-190b, miR-584-5p, miR-452-5p, and miR-1306-5p) is capable of classifying luminal and non-luminal breast cancers.

Faranak Farahmand^{1¶}, Saied Rahmani^{2,6¶}, Hadi Bayat¹, Adel Salimi², Sogol Ghanbari¹, Afsaneh Malekzadeh Shafaroudi³, Ali Sharifi-Zarchi², Mohammad Vasei⁴, Seyed-Javad Mowla^{1,5*}

Affiliations:

1. Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
2. Department of Computer Engineering, Sharif University of Technology, Tehran, Iran
3. Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
4. Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
5. TechAzma Company, Tehran, Iran
6. Institute for Research in Fundamental Sciences (IPM), Tehran, Iran

¶ Co-First authors, these authors contributed equally to this work

* Corresponding author: Dr. Seyed Javad Mowla, Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Jalal Al Ahmad, Nasr, Tehran, Iran. Tel.: +9821-82883464; Fax: +9821-82884717; E-mail: sjmowla@modares.ac.ir

Abstract.

BACKGROUND: Identifying the molecular subtypes of breast cancer (BC) plays a crucial role in enhancing the efficacy of therapy. MiRNAs (miRs) with differential expressions in different subtypes of breast tumors can be considered as non-invasive biomarkers for diagnosing BC subtypes.

OBJECTIVE: We aimed to investigate the efficacy of miR-190b, miR-584-5p, miR-452-5p, and miR-1306-5p as novel potent diagnostic biomarkers in discriminating patients with luminal (ER+) and non-luminal (ER-) BCs.

METHODS: A group of miRs significantly associated with estrogen cell receptors (ER) in breast tumors were identified using feature selection methods analysis on miR-Seq datasets retrieved from TCGA and GSE68085. Four abovementioned miRs were selected as novel potential biomarkers, and their relative expression levels were assessed within adjacent non-tumor, ER+ and ER- tumor tissues by quantitative RT-PCR. Their impact on diagnosis was also evaluated by ROC curve analysis.

RESULTS: In ER+ BCs compared to ER- BCs, the expression of miR-190b was remarkably increased, while the expression of miR-584-5p, miR-452-5p, and miR-1306-5p were significantly decreased. This group could discriminate ER+ and ER- BCs at an AUC of 0.973.

CONCLUSIONS: According to our findings, these four miRs are promising biomarkers in discriminating BC subtypes. The candidate miRs in parallel with histologic diagnosis methods can be applied for identifying patients who are most likely responding to specific therapies based on ER status.

Keywords: Breast Cancer, Luminal tumor, non-Luminal tumor, Estrogen Receptors, miRNAs, Biomarker

1 **1 Introduction**

2 Breast cancer (BC) has been the leading cause of cancer death (15.5%) and the most common
3 cancer in females (24.5%) worldwide [1]. Despite significant improvements in the understanding
4 of cancer pathogenesis, screening programs for early diagnosis, and treatment over the past few
5 decades, there are still about 2.2 million new cases of BCs with more than half a million BC-
6 related deaths recorded annually worldwide [1]. BC has heterogeneous nature with various
7 morphologic signs and clinical outcomes which can be categorized in several aspects, including
8 clinical features, expression of tumor markers, and histologic types [2, 3]. In this regard, gene
9 expression profile analyses have led to the classification of BCs based on hormone receptors,
10 including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth
11 factor receptor (HER2 or HER2/neu) status. The hormone receptors are crucial factors in
12 therapeutic prediction and should be measured on all newly diagnosed BC tumors [4-7]. ER and
13 PR mediate mammary cell proliferation signals and stimulate the growth of both normal and
14 neoplastic breasts [8]. Likewise, HER2 is a transmembrane receptor tyrosine kinase in the
15 epidermal growth factor receptor family [8]. Accordingly, the intrinsic molecular subtypes of BC
16 were classified as luminal A (ER+/PR±/HER2-), luminal B (ER+/PR±/HER2+), HER2 enriched
17 (ER-/PR-/HER2+), basal-like, and normal-like, which show specific biological features and
18 clinical outcomes [6].

19 In the clinical aspect, the ER expression is frequently examined by immunohistochemistry of
20 biopsy to separate BC subtypes. This examination provides information on prognosis and the
21 possibility of response to endocrine therapy [9]. However, the main disadvantage of this assay is
22 false-negative results, which contribute to patients being denied for hormone therapy.
23 Furthermore, diagnosis based on tissue biopsy is also an invasive process with the risk of

24 spreading tumor cells to adjacent tissues [10, 11]. Therefore, considering the limitations of
25 common diagnostic tests, developing new assays with high sensitivity and specificity for BC
26 subtypes determination is indispensable. In this regard, biomarkers are now investigated in
27 cancer studies for the purpose of diagnosis, prognosis, and therapy [12].

28 MiRNAs (miRs) are a class of small non-coding RNAs with 19–25 nucleotides length. The miRs
29 can post-transcriptionally regulate gene expression by binding to the target mRNA and affecting
30 many biological processes such as differentiation, proliferation, apoptosis, and metastasis [13].

31 Dysregulated miRs play primary roles in cancer initiation and progression [12, 13]. During
32 recent years, an increasing number of miRs acting either as oncogenes or tumor suppressors have
33 been investigated in BC [14]. Due to remarkable stability and easily non-invasive detection in

34 biological fluids, such as serum and plasma, miRs are considered as promising biomarkers in
35 cancer diagnosis and prognosis [12, 15-18]. Hence, numerous studies have reported expression
36 patterns of miRs as an informative tool for the classification of BCs [19, 20]. Although several

37 studies have been tried to discover biomarkers based on miRs, the exploration of novel groups of
38 miRs with high sensitivity and specificity for the diagnosis of BC subtypes is valuable for
39 developing diagnosis strategies, specific treatment, and disease management. The main purpose

40 of the present study was to identify novel promising miR biomarkers which are associated with
41 the presence of ER in BCs. For this aim, we utilized boruta [21], XGBoost [22], and limma [23]
42 R packages for TCGA and GEO datasets analysis. Moreover, quantitative RT-PCR (qRT-PCR)

43 method was used to validate experimentally the efficacy of our candidate miR biomarkers in
44 discriminating luminal (ER+) from non-luminal (ER-) BCs. Furthermore, we evaluated the role
45 of the candidate miRs as biomarker for BC diagnosis by measuring their expression in breast

46 tumor and non-tumor samples of the TCGA dataset and those samples which were used in the

47 qRT-PCR analysis. Finally, we confirmed the efficacy of miR-190b (miR-190b is classified as
48 miR-190b-3p and -5p in the latest version of miRBase sequence database (release 22.1), Here,
49 our candidate is miR-190b-5p), miR-584-5p, miR-452-5p, and miR-1306-5p as the promising
50 biomarkers of luminal (ER+) and non-luminal (ER-) breast tumors.

51

52 **2 Materials and methods**

53 *2.1. Analysis of miR-Seq datasets*

54 Raw read counts of miR-seq dataset of BC patients along with their clinical dataset from TCGA
55 [24] were obtained and analyzed by TCGAbiolinks package [25]. The total number of samples in
56 this dataset was 1175 (1072 tumor and 103 adjacent non-tumor samples). Intrinsic subtype labels
57 were assigned to samples according to the expression level of ER, PR, and HER2 from IHC test
58 results reported in clinical data. Information about the BC subtypes based on the cell receptors
59 (ER, PR, and HER2) was presented in positive/negative and level of existence format. In
60 addition to TCGA, raw read counts of the miR-seq dataset of patients with TNBC and luminal
61 (ER+) BCs were obtained from GSE68085 [26].

62 Here, we applied boruta feature selection, XGBoost feature selection, and limma differential
63 expression analysis on TCGA and GSE68085 datasets. To merge the results of different feature
64 selection methods on a dataset in a statistically acceptable manner, the Stuart method from the
65 ‘RobustRankAggreg’ package in R was used. Also, in the other cases that we need to merge
66 multiple ordered lists, we utilize the same strategy. After investigating miRs that are significantly
67 associated with the existence of cell receptors in breast tumors, we used the ggplot2 R package to
68 generate box plots by which we could evaluate the differential expressions of the top ten miRs
69 with the highest association to ER between luminal (ER+) and non-luminal (ER-) breast tumor

70 samples in miR-seq datasets. We also reviewed the related previous studies to identify those
71 miRs which have not been previously reported as biomarkers for BC subtypes. A group of miRs
72 which have not been previously reported as biomarkers for BC subtypes, were selected.

73

74 2.2. *Patients and samples*

75 This research involved using archived samples that were collected from October 2018 to June
76 2019 and the study were conducted from October 2020 to September 2021. BC tissue specimens
77 were collected from Khatam-ol-Anbia and Rasule-Akram hospitals, they were immediately snap-
78 frozen in liquid nitrogen after surgery and were stored at -80°C at Tarbiat Modares University.
79 Tissue samples were categorized into 36 pairs of breast tumors and their adjacent non-tumor
80 tissues, plus 13 breast tumor samples. All tumor samples were examined by pathologists and
81 classified according to the standard histopathological parameters. Clinicopathological
82 characteristics of patients are summarized in **Supplementary Table 1**. The research protocol for
83 in vitro experiments on tissue samples was approved by the ethics committee of Ferdowsi
84 University of Mashhad (code number: IR.UM.REC.1399.104). No experiments were conducted
85 on human subjects or animals. Authors have no access to the information that could identify
86 individual participants during or after data collection.

87

88 2.3. *RNA extraction*

89 For isolating the total RNA from breast tissues, RiboEx Total RNA reagent (GeneAll
90 Biotechnology, South Korea) was used. The concentration of the extracted RNA was then
91 quantified using a NanoDrop™ spectrophotometer. The purity of the RNA was validated by
92 measuring the ratio of the absorbance at 260 and 280 nm. The quality of RNA, which is regarded

93 as the absence of degraded RNA, was evaluated by agarose gel electrophoresis and ethidium
94 bromide staining. Accordingly, the 18S and 28S RNA bands were visualized under ultraviolet
95 light.

96 2.4. *Polyadenylation and cDNA synthesis*

97 Following RNA isolation, 1 µg of total RNA was poly-adenylated using Poly(A) Polymerase
98 Tailing Kit (New England Biolabs., UK., Ltd.) according to manufacture protocol. Then, the
99 poly-adenylated RNA (10 µl) was converted to complementary DNA (cDNA) by adding
100 Anchored Oligo(dT) and using RevertAid M-MuLV RT (Thermo Fisher Scientific., UK) as the
101 protocol provided by corresponding manufacture. The prepared cDNA was used for
102 quantification of miR-190b, miR-584, and miR-1306.

103

104 2.5. *Stem-loop RT-PCR and cDNA synthesis*

105 Stem-loop reverse transcription was performed for miR-452 using stem-loop primers. Then,
106 reverse transcriptase reaction was performed using RevertAid M-MuLV RT (Thermo Fisher
107 Scientific., UK).

108

109 2.6. *qRT-PCR*

110 Ultimately, qRT-PCR was performed to quantitatively assess the expression of our selected miRs
111 in tissue samples using appropriate primer sets (**Supplementary Tables 2 and 3**). Syber Green
112 PCR Master Mix (BIOFACT Co., Ltd., Korea) and primers listed in (**Supplementary Tables 2**
113 **and 3**) were utilized for qRT-PCR, which was conducted on a StepOne Plus System. Mean delta
114 Ct values of triplicate real-time qRT-PCR amplifications were utilized in statistical analysis. The
115 comparative delta Ct values ($\Delta Ct = Ct_{miRs} - Ct_{U-48}$) and $\text{Log } 2^{-\Delta Ct}$ were used as the

116 relative quantification of miRNAs, using the U48 small RNA [27-29] for normalization. All the
117 amplified candidate miRs which TA-cloned using pGEM-T easy vector kit (Promega; USA).
118 Finally the accuracy of cloned sequences were confirmed by the golden standard sequencing
119 method.

120

121 2.7 *Statistical analysis*

122 GraphPad Prism ver. 8 (GraphPad Software Inc., La Jolla, CA, USA) was applied for statistical
123 analysis of the results obtained by qRT-PCR. The two-tailed Mann-Whitney test was used to
124 compare the differential expression level of selected miRs within the ER+ and ER- breast tumor
125 samples.

126 The Wilcoxon test was used for comparison of our selected miRs expression level between
127 breast tumor and their adjacent non-tumor tissues. Results with p-value < 0.05 were considered
128 as significant.

129

130 2.8 *ROC Curve analysis*

131 Receiver operating characteristic (ROC) curves were also plotted by the pROC package [30] to
132 validate the capability of the candidate miRs to distinguish between ER+ and ER- tumor samples
133 and between breast tumors and their adjacent non-tumor samples. This was performed both
134 individually and for a combination of all selected miRs. The area under curve (AUC) was also
135 employed for evaluation of the specificity and sensitivity of the candidate miRs in distinguishing
136 ER+ and ER- tumor samples and their adjacent non-tumor tissues; the higher AUC shows better
137 diagnostic performance (the AUCs closer to 1 reflect more substantial differences).

138 **3 Results**

139 *3.1. The candidate miRs associated with ER in breast tumors*

140 The miRs with the highest possibility of being associated with ER were identified and ordered
141 using limma, xgboost, bruta and aggregated by the RobustRankAggreg package. Boruta is an R
142 package utilizing a random forest model to classify data. XGBoost is also an R package that
143 provides a regression and classification model based on tree models and the ensemble technique.
144 Further, we combined all the results to reach the most generalizable miR biomarkers. We
145 suppose that several miRs are significantly associated with the existence of cell receptors;
146 therefore, this association should be found in most of the datasets and by the majority of methods
147 without considering methods and experiment biases. The final result of a feature selection
148 method on a dataset is an ordered list of miRs. As we aimed to investigate potential biomarkers
149 of luminal (ER+) and non-luminal (ER-) breast tumors, we focused our study on the top ten
150 most strongly ER associated miRs (**Table 1**). The expression status of these top ten miRNAs in
151 BC were investigated in UCSC genome browser (GRCH37/hg19), and their differential
152 expression were investigated in ER+ and ER- breast tumor samples of TCGA (**Supplementary**
153 **Fig. 1**). We excluded miR-577 and miR-452-3p from the top ten list due to their extremely low
154 expression levels in breast tumors. The first rank miR-190b with the highest score in the list was
155 selected as the potential biomarker of ER+ breast tumors. The expression levels and the
156 association of miR-18a-5p [31], miR-505-3p [32], miR-224-5p [33, 34], and miR-135b-5p [35]
157 with ER have been previously investigated in breast cancer. Therefore, we excluded miR-18a-5p,
158 miR-505-3p, miR-224-5p, and miR-135b-5p from this study, and we selected those miRs which
159 their association with highly aggressive breast tumors (ER-) have not been previously studied. In
160 this regard, miR-584-5p, miR-452-5p, and miR-1306-5p were selected to evaluate their potential
161 as biomarkers of ER- breast tumors.

162

Table 1. Top-ranked most strongly ER associated miRNAs.

ER	Aggregate Score
miR-190b	0.000032
miR-18a-5p	0.000256
miR-505-3p	0.002304
miR-224-5p	0.00484
miR-577	0.005816
miR-135b-5p	0.007
miR-584-5p	0.01024
miR-452-5p	0.065408
miR-452-3p	0.075656
miR-1306-5p	0.114264

163

The results of the RobustRankAggreg package analysis of miRseq datasets are summarized in this table.

164

MiRNAs with a lower aggregate score are associated to ER receptors with a higher probability. Our

165

candidate miRNAs are in bold style.

166

167 3.2. Evaluation of miR-190b expression level in ER+ compared to ER- breast tumors

168 Our *in-silico* analysis on the miR-seq datasets in TCGA (**Fig. 1A**) and GSE68085 (**Fig. 1B**)

169 databases, elucidated higher expression level of miR-190b in ER+ compared to ER- breast

170 tumors (P. Value < 0.05). Moreover, as shown in **Fig. 1C**, the expression level of miR-190b

171 correlated positively with the percentage of ER level in breast tumors, which indicates that the

172 higher the ER level is, the more miR-190b is expressed in breast tumors. The results of qRT-

173 PCR confirmed our *in-silico* analysis (**Fig. 1D**). Indeed, we found a similar significant higher

174 expression level of miR-190b in 24 ER+ compared to 23 ER- breast tumor samples (P. Value <

175 0.05).

176

177 **Fig. 1: The expression of miR-190b in patients with ER+ compared to ER- BCs.** The *in-silico* analysis of the
178 miR-seq data of BC patients in TCGA (A) and GSE68085 (B) showed a significant upregulation of miR-190b in
179 ER+ versus ER- breast tumor samples (P. Value < 0.05). C) The *in-silico* evaluation of miR-190b expression based
180 on ER percentage level showed a positive correlation between miR-190b and ER expression level.
181 D) The results of the qRT-PCR analysis also showed that the expression of miR-190b (relative to u-48) in ER+
182 breast samples is significantly higher than ER- breast samples (P. Value < 0.05).

183

184 3.3. *Evaluation of the expression of miR-584, miR-452, and miR-1306 in ER+ compared to*
185 *ER- breast tumors*

186 We validated the significant downregulation of miR-584, miR-452, and miR-1306 in ER+
187 compared to ER- breast tumors by qRT-PCR (Fig. 2D), which was predicted by analyzing the
188 available miR-seq datasets in TCGA (Fig. 2A) and GSE68085 (Fig. 2B) (P. Value < 0.05).
189 In *in-silico* analysis, a negative correlation between the percentage of ER level and the
190 expression of miR-584, miR-452, and miR-1306 was also observed in breast tumors (Fig. 2C).

191

192 **Fig. 2: The expression of miR-584, miR-452, and miR-1306 in patients with ER+ compared to ER- BCs.** The
193 results of *in-silico* analysis of the miR-seq dataset of BC patients in TCGA (A) and GSE68085 (B) showed
194 downregulation of miR-584, miR-452, and miR-1306 (P. Value < 0.05) in ER+ versus ER- breast tumor samples.
195 C) The *in-silico* evaluation of the expression of miR-584, miR-452, and miR-1306 based on the percentage of ER
196 level indicated a significant negative correlation between these three miRs and ER expression level (P. Value <
197 0.05). D) The qRT-PCR analysis also showed that the expression of miR-584, miR-452, and miR-1306 (relative to
198 u-48) in ER+ breast samples is significantly lower than ER- breast samples (P. Value < 0.05).

199

200 3.4. *Evaluation of Differential expression of our four selected miRs between breast tumor and*
201 *non-tumor samples*

202 At first, expression profiles of the selected miRs between breast tumor and non-tumor samples
203 (adjacent non-tumor breast tissues) in TCGA datasets were determined by *in-silico* analysis.
204 Then, the expression of the candidate miRs were evaluated experimentally in 36 breast tumor
205 cases and their adjacent non-tumor tissues by qRT-PCR analysis. Although *in-silico* evaluation
206 of miR-190b expression in breast tumors compared to non-tumor breast samples of TCGA data
207 showed a significant upregulation (**Fig. 3A**), the qRT-PCR analysis showed an opposite results
208 (**Fig. 3B**). Further analysis indicated that the downregulation of miR-190b in breast tumors was
209 restricted to ER⁻/PR⁻ tumors while ER⁺/PR⁺ and ER⁺/PR⁻ tumors showed the upregulation of
210 miR-190b compared to non-tumor breast tissues (**Fig. 3C and D**). Therefore, the upregulation or
211 downregulation of miR-190b in tumor samples versus non-tumor samples is dependent on the
212 ER status.

213
214 **Fig. 3: The expression of miR-190b (relative to U-48) in breast tumor samples compared to non-tumor**
215 **adjacent tissues. A)** The results of *in-silico* analysis showed a significant increase of miR-190b expression in breast
216 tumors compared to non-tumor breast samples of TCGA data (P. Value < 0.05). **B)** However, the results of the qRT-
217 PCR analysis showed an overall decrease of miR-190b expression in tumor tissues versus non-tumor adjacent
218 tissues (P. Value < 0.05). The qRT-PCR analysis also showed that miR-190b was up-regulated in ER⁺ tumors (**C**),
219 whereas it was downregulated in ER⁻ tumors compared to non-tumor adjacent tissues (**D**).

220
221 MiR-584-5p, miR-452-5p, miR-1306 showed lower expression in breast tumor samples (both
222 ER⁺ and ER⁻) compared to non-tumor breast tissues based on both miR-seq (**Fig. 4A, B, and C**)
223 and qRT-PCR analysis (**Fig 4D, E, and F**). Although, in *in-silico* analysis of miR-seq datasets,
224 miR-1306 didn't show significant differential expression between breast tumor and non-tumor

225 adjacent samples (**Fig. 4C**), in the qRT-PCR analysis, it was significantly down-regulated in
226 breast tumor tissues compared to their adjacent non-tumor tissues (p-value < 0.05) (**Fig. 4F**).

227

228 **Fig. 4: The expression of miR-584, miR-452, and miR-1306 (relative to U-48) in breast tumor samples**
229 **compared to non-tumor adjacent tissues.** The results of in-silico analysis showed that the expression of miR-584
230 (**A**), and miR-452 (**B**) are significantly lower in breast tumors, as compared with non-tumor breast samples of
231 TCGA (P. Value < 0.05), while the expression level of miR-1306 (**C**) showed no significant difference between
232 breast tumors and non-tumor breast samples. The results of the qRT-PCR analysis showed significant
233 downregulation of miR-584 (**D**), miR-452 (**E**), and miR-1306 (**F**) in tumor tissues versus non-tumor adjacent tissues
234 (P. Value < 0.05).

235

236 3.5. *Roc Curve analysis*

237 The four candidate miRs, miR-190b, miR-584, miR-452 and miR-1306, showed high AUCs with
238 values of 0.951 (specificity of 86%, and sensitivity of 94%), 0.851 (specificity of 82%, and
239 sensitivity of 75%), 0.846 (specificity of 79%, and sensitivity of 81%), and 0.80 (specificity of
240 72%, and sensitivity of 78%), respectively (**Fig. 5A, B, C, and D**). Interestingly, the AUC of the
241 combination of miR-190b, miR-584, miR-452, and miR-1306 increased to 0.973 with the
242 specificity of 92% and sensitivity of 96% in discriminating ER+ and ER- samples of TCGA
243 dataset (**Fig. 5E**). A ROC curve was also plotted for the combination of miR-190b, miR-18a-5p,
244 miR-505-3p, miR-224-5p, miR-135b-5p, miR-584-5p, miR-452-5p, and miR-1306-5p which
245 created the similar AUC value of 0.977 (**Supplementary Fig. 2**). Therefore, the addition of miR-
246 18a-5p, miR-505-3p, miR-224-5p, and miR-135b-5p did not add values to the AUC achieved by
247 the combination of our selected miRs (Both groups represented the AUC of 0.97). In addition to
248 the ROC curves obtained by the in silico analysis of TCGA datasets, the pROC package was
249 used to evaluate the diagnostic value of our selected miRs in discriminating ER+ from ER-

250 tissue samples used in the qRT-PCR analysis. In concordance with AUCs obtained for miR
251 levels in TCGA datasets, significant AUCs of 0.961 (Specificity of 71%, and sensitivity of 63%),
252 0.674 (Specificity of 69%, and sensitivity of 61%), 0.777 (Specificity of 87%, and sensitivity of
253 69%), and 0.666 (Specificity of 77%, and sensitivity of 52%) have been obtained for miR-190b
254 (**Fig. 5F**), miR-584 (**Fig. 5G**), miR-452 (**Fig. 5H**), and miR-1306 (**Fig. 5I**) respectively (P. Value
255 < 0.05).

256

257 **Fig. 5: The AUCs of ROC curves for miR levels in ER+ and ER- samples.** The capabilities of miR-190b (**A** and
258 **F**), miR-584 (**B** and **G**), miR-452 (**C** and **H**), miR-1306 (**D** and **I**), and the combination of these four miRs (**E**) to
259 discriminate ER+ and ER- samples of TCGA datasets (**A**, **B**, **C**, **D**, and **E**) and qRT-PCR analysis (**F**, **G**, **H**, and **I**)
260 are shown in ROC curves.

261

262 As shown in the qRT-PCR results, miR-190b was up-regulated in ER+ breast tumors, whereas it
263 was down-regulated in ER- tumors compared to non-tumor tissues. Therefore, we excluded this
264 miR from the group of biomarkers which efficiency was evaluated in the detection of breast
265 tumors. Accordingly, ROC curves were plotted for miR-584, miR-452, and miR-1306 expression
266 in TCGA datasets, which represented the AUCs of 0.961 (specificity of 90%, and sensitivity of
267 91%), 0.926 (specificity of 93%, and sensitivity of 82%), and 0.725 (specificity of 63%, and
268 sensitivity of 74%) (**Fig. 6A**, **B**, and **C**). The AUCs of 0.939 (specificity of 97%, and sensitivity
269 of 86%), and 0.982 (specificity of 91%, and sensitivity of 95%) were also generated for the
270 combination of miR-584 and miR-452, and the combination of miR-584, miR-452, and miR-
271 1306 (**Fig. 6D** and **E**).

272 Furthermore, the ROC curves generated for the expression of miR-584, miR-452, and miR-1306
273 in tumor and adjacent non-tumor samples of qRT-PCR analysis represented the AUC values of

274 0.766 (specificity of 64%, and sensitivity of 78%), 0.666 (specificity of 68%, and sensitivity of
275 60%), and 0.705 (specificity of 61%, and sensitivity of 75%) (**Fig. 6F, G, and H**).

276

277 **Fig. 6: The AUCs of ROC curves for mi levels in tumor and non-tumor samples.** The potential of miR-584 (A
278 and F), miR-452 (B and G), miR-1306 (C and H), the combination of miR-584 and miR-452 (D), and the
279 combination of all these three miRs (E) to discriminate tumor and non-tumor samples of TCGA (A, B, C, D, E) and
280 qRT-PCR analysis (F, G, H) are shown in ROC curves.

281

282 **4 Discussion**

283 In the current study, we aimed to identify ER associated miRs to reach promising biomarkers.
284 Therefore, we used the available data from TCGA and applied boruta and XGBoost feature
285 selection and limma differentially expression analysis to obtain miRs that are significantly
286 associated with the existence of cell receptors in breast tumors. As a result, we reported the
287 discovery of four miRNAs, miR-190b, miR-584-5p, miR-452-5p, and miR-1306-5p, which are
288 significantly associated with ER status in breast tumors, as predicted by *in silico* analysis. We
289 then confirmed the efficacy of this signature in discriminating luminal BCs (ER+) and non-
290 luminal BCs (ER-) by qRT-PCR.

291 Currently, Mammography is the golden standard tool for screening and diagnosis of breast
292 cancer (BC). However, invasive histological evaluation of breast biopsy is required for accurate
293 diagnosis of the BC subtype. The identification of novel, reliable, and minimally invasive BC
294 biomarkers with high sensitivity and specificity would lead to a significant improvement in the
295 clinical management of this complex disease [36]. Numerous studies have reported the
296 significant role of miRs in the initiation and progression of BC and revealed that certain miRs are
297 differentially expressed between different breast tumor subtypes. [37]. Hence, the differentially

298 expressed miRs can be considered as a promising molecular biomarkers for distinguishing BC
299 subtypes.

300 It has been reported that miR-190b is associated with ER+ breast tumors [38] and resistance to
301 hormone therapy [39]. Furthermore, Cizeron-Clairac et al. reported that miR-190b is
302 significantly upregulated in ER+ compared to ER- tumors. In consistent with previous studies,
303 our results also demonstrated the significant higher expression level of miR-190b in ER+
304 compared to ER- breast tumors (P. Value < 0.05). Moreover, ROC curve analysis showed the
305 potential diagnostic value of miR-190b as a very remarkable biomarker in distinguishing ER+
306 from ER- breast tumors with the AUC of 0.951 (based on *in-silico* analysis). In another study,
307 the expression of miR-190b was examined in seven BC cell lines and suggested that the
308 biological and clinical implication of miR-190b may differ among BC subtypes [40].
309 Furthermore, de Anda-Jáuregui et al. showed the upregulation of miR-190b in ER+ breast
310 tumors compared to normal breast tissues, whereas the downregulation of miR-190b in ER-
311 tumors compared to healthy controls [38]. In the present study, our *in-silico* analysis represented
312 an overall upregulation of miR-190b in breast tumors versus adjacent non-tumor tissue. While in
313 the practical experiment, we observed the upregulation of miR-190b in ER+ but not in ER-
314 breast tumors compared to non-tumor tissues. Hence, it should be noted that the upregulation of
315 miR-190b in breast tumor samples versus non-tumor adjacent tissues was restricted to ER+
316 tumors. This discrepancy between the results of *in-silico* and qRT-PCR analysis may be
317 attributed to the higher number of ER+ tumors compared to ER- tumors in the TCGA dataset.

318 Previous studies mostly have focused on the role of miR-584 in lung cancer progression and
319 metastasis [41-43]. The chromosomal region where miR-584 is located, 5q32, has been
320 highlighted to be deleted in myelodysplastic syndromes that lead to malignant transformation

321 [44, 45]. In addition, a study indicated that miR-584 may act as a tumor suppressor in renal
322 carcinoma cells [46]. Furthermore, it was revealed that miR-584 is significantly down-regulated
323 in human HER2+ breast tumors compared to non-tumor adjacent tissues [47]. Our results also
324 showed significant downregulation of miR-584 in breast tumors compared to adjacent non-tumor
325 tissues, which may indicate the tumor suppressive role of miR-584. According to ROC curve
326 analysis, miR-584 also can act as a strong biomarker for BC diagnosis with high sensitivity and
327 specificity (AUC of 0.961 and 0.766 in *in-silico* and qRT-PCR analysis, respectively).
328 Additionally, our findings validated the downregulation of miR-584 in ER+ versus ER- breast
329 tumors predicted by *in silico* analysis, and the AUC values of 0.851 and 0.674 obtained by *in-*
330 *silico* and qRT-PCR analysis that represented the notable capability of miR-584 in distinguishing
331 ER- and ER+ BC subtypes.

332 It is reported that miR-452 is expressed aberrantly in different types of human cancer [48-50].
333 The downregulation of miR-452 in BC tissues compared with paired normal breast tissues was
334 also identified previously [51]. Moreover, miR-452 has been predicted to have an important role
335 in regulation of pathways specific to luminal-A by TCGA data analysis [52]. In the present
336 study, we also demonstrated the downregulation of miR-452 in breast tumors versus adjacent
337 non-tumor tissues. More importantly, for the first time to our knowledge, we showed that miR-
338 452 could serve as a potential biomarker for distinguishing ER- from ER+ breast tumors with
339 high sensitivity and specificity (AUC values of 0.846 and 0.777 by *in-silico* and qRT-PCR
340 analysis, respectively).

341 The aberrant expression of miR-1306 was observed in plasma samples of patients with different
342 diseases such as heart failure, glaucoma, or epilepsy [53]. Moreover, the dysregulation of miR-
343 1306 has been reported in human breast and colorectal cancers [53, 54]. Likewise, the

344 upregulation of miR-1306-5p was observed in subjects with malignant breast lesions compared
345 to benign tumors [53]. Our study represented the upregulation of miR-1306 in ER– breast tumors
346 which typically are more aggressive than ER+ tumors. However, the downregulation of miR-
347 1306 in breast tumors compared to non-tumor adjacent tissues may suggest its tumor suppressive
348 role. This discrepancy needs to be elucidated in future studies. Likewise, no previous study has
349 been performed to investigate the expression level and biological roles of miR-1306 in BC
350 subtypes. Hence, this is the first study to our knowledge, that reveals the efficacy of miR-1306-
351 5p in distinguishing ER+ and ER– breast tumors with AUC values of 0.799 and 0.666 based on
352 *in-silico* and qRT-PCR analysis, respectively.

353 Overall, the AUCs acquired by qRT-PCR were not as high as those of *in-silico* analysis. This
354 discrepancy can be attributed to the much higher number of breast tumor samples of TCGA
355 datasets compared to the samples used in qRT-PCR. For identifying the best biomarker panel, we
356 compared the AUCs produced from ROC curve analysis for each individual miR and their
357 combination profiles in distinguishing ER+ and ER– BC samples of TCGA. It was revealed that
358 the best AUC of 0.973 can be achieved from the combination of miR-190b, miR-584, miR-452,
359 and miR-1306, providing specificity of 92% and sensitivity of 96%.

360 The ROC curve for the combination of the miR-584-5p, miR-452, and miR-1306 in breast
361 tumors and non-tumor samples of TCGA showed an exceptionally high diagnostic accuracy with
362 an AUC value of 0.982 with the specificity of 91% and sensitivity of 95%. It should be noted
363 that miR-190b was not included in this biomarker set because its differential expression in breast
364 tumors compared to non-tumor tissues depends on the tumor subtype. Although the signature of
365 miR-584, miR-452, and miR-1306 is an effective diagnostic test alone with a strong performance

366 (specificity of 100% and sensitivity of 87%), it may show promise as a valuable assessment tool
367 in BC diagnosis in combination with screening mammography.

368 A particular strength of this study is that the reported mi panel is probably less prone to
369 biological differences than a single miR. Therefore, the miR panels are more reliable for clinical
370 use. A second strength is that the measured expression level of the four candidate miRs in breast
371 tumor samples revealed a specific algorithm that helps to detect the ER status of each sample. To
372 clarify, in ER+ tumors, the expression level of miR-190b was higher than that of miR-584, miR-
373 452, and miR-1306, while, in ER– tumors the results were vice versa (**Supplementary Fig. 3**).
374 However, since the miR-452 expression level was not detectable in a number of tumor samples,
375 the role of miR-452 in this algorithm needs further investigations.

376

377 **5 Conclusion**

378 Overall, our study signified the discovery of a panel of four miRs (miR-190b, miR-584-5p, miR-
379 452-5p, and miR-1306-5p), which expression have association with ER in breast tumors, for
380 diagnosis of luminal (ER+) and non-luminal (ER–) BC subtypes. According to this miR panel,
381 we have represented a classification model with high discrimination ability in classifying ER+
382 and ER– BCs at an AUC of 0.973. Interestingly, a straightforward classification was introduced
383 based on the seesaw expression pattern of miR-190b compared to the other three miRs to
384 distinguish ER– and ER+ samples. In addition, the panel containing miR-584, miR-452, and
385 miR-1306 was shown to have the efficacy to be developed as a parallel test to examine breast
386 samples of patients with abnormal screening mammograms, with the aim of reducing false-
387 positive results. For future investigations, these two miR signatures should be evaluated in blood
388 serum samples to confirm the clinical utility of these miR signatures.

389

390 **Acknowledgments**

391 Not applicable.

392

393 **Author contributions**

394 **Conception:** Faranak Farahmand

395 **Interpretation or analysis of data:** Faranak Farahmand, Saeid Rahmani, Hadi Bayat

396 **Preparation of the manuscript:** Faranak Farahmand, Saeid Rahmani

397 **Revision for important intellectual content:** Faranak Farahmand, Saeid Rahmani, Seyed-Javad

398 Mowla, Hadi Bayat, Adel Salimi, Sogol Ghanbari, Ali Sharifi-Zarchi, Mohammad Vasei

399 **Supervision:** Seyed-Javad Mowla

Uncategorized References

1. Sung, H., et al., *Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA: a cancer journal for clinicians, 2021. **71**(3): p. 209-249.
2. Coleman, W.B. and C.K. Anders, *Discerning clinical responses in breast Cancer based on molecular signatures*. The American journal of pathology, 2017. **187**(10): p. 2199-2207.
3. Li, C., D. Uribe, and J. Daling, *Clinical characteristics of different histologic types of breast cancer*. British journal of cancer, 2005. **93**(9): p. 1046-1052.
4. Hu, Z., et al., *The molecular portraits of breast tumors are conserved across microarray platforms*. BMC genomics, 2006. **7**(1): p. 1-12.
5. Chen, Y.-J., et al., *Molecular subtyping of breast cancer intrinsic taxonomy with oligonucleotide microarray and NanoString nCounter*. Bioscience reports, 2021. **41**(8).
6. Perou, C.M., et al., *Molecular portraits of human breast tumours*. nature, 2000. **406**(6797): p. 747-752.
7. Song, N., et al., *Prediction of breast cancer survival using clinical and genetic markers by tumor subtypes*. PLoS One, 2015. **10**(4): p. e0122413.
8. Joshi, H. and M.F. Press, *Molecular oncology of breast cancer*, in *The Breast*. 2018, Elsevier. p. 282-307. e5.
9. Hironaka-Mitsunashi, A., et al., *A tissue microRNA signature that predicts the prognosis of breast cancer in young women*. PLoS One, 2017. **12**(11): p. e0187638.
10. Jorns, J.M., *Breast cancer biomarkers: challenges in routine estrogen receptor, progesterone receptor, and HER2/neu evaluation*. Archives of Pathology & Laboratory Medicine, 2019. **143**(12): p. 1444-1449.
11. Alba-Bernal, A., et al., *Challenges and achievements of liquid biopsy technologies employed in early breast cancer*. EBioMedicine, 2020. **62**: p. 103100.
12. Adhami, M., et al., *Candidate miRNAs in human breast cancer biomarkers: a systematic review*. Breast Cancer, 2018. **25**(2): p. 198-205.
13. Stahlhut, C. and F.J. Slack, *MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications*. Genome medicine, 2013. **5**(12): p. 1-12.
14. Mu, H., et al., *miRNAs as potential markers for breast cancer and regulators of tumorigenesis and progression*. International Journal of Oncology, 2021. **58**(5): p. 1-12.
15. Arun, R.P., H.F. Cahill, and P. Marcato, *Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention*. Biomedicines, 2022. **10**(3): p. 651.
16. Gupta, I., et al., *Circulating miRNAs in HER2-positive and triple negative breast cancers: potential biomarkers and therapeutic targets*. International Journal of Molecular Sciences, 2020. **21**(18): p. 6750.
17. Zhang, Y., et al., *Multilayer network analysis of miRNA and protein expression profiles in breast cancer patients*. PloS one, 2019. **14**(4): p. e0202311.
18. Schrauder, M.G., et al., *Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection*. PloS one, 2012. **7**(1): p. e29770.
19. Kudela, E., et al., *miRNA expression profiles in luminal A breast cancer—implications in biology, prognosis, and prediction of response to hormonal treatment*. International Journal of Molecular Sciences, 2020. **21**(20): p. 7691.

20. Dvinge, H., et al., *The shaping and functional consequences of the microRNA landscape in breast cancer*. Nature, 2013. **497**(7449): p. 378-382.
21. Kursa, M.B. and W.R. Rudnicki, *Feature selection with the Boruta package*. J Stat Softw, 2010. **36**(11): p. 1-13.
22. Chen, T., et al., *xgboost: Extreme Gradient Boosting (2017)*. R package version 0.6-4, 2015.
23. Ritchie, M.E., et al., *limma powers differential expression analyses for RNA-sequencing and microarray studies*. Nucleic acids research, 2015. **43**(7): p. e47-e47.
24. Chang, K., et al., *The cancer genome atlas pan-cancer analysis project*. Nat Genet, 2013. **45**(10): p. 1113-1120.
25. Colaprico, A., et al., *TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data*. Nucleic acids research, 2016. **44**(8): p. e71-e71.
26. Krishnan, P., et al., *Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer*. BMC genomics, 2015. **16**(1): p. 1-17.
27. Xiang, M., et al., *U6 is not a suitable endogenous control for the quantification of circulating microRNAs*. Biochemical and biophysical research communications, 2014. **454**(1): p. 210-214.
28. Hirschberger, S., et al., *Identification of suitable controls for miRNA quantification in T-cells and whole blood cells in sepsis*. Scientific reports, 2019. **9**(1): p. 1-13.
29. Carvalho, T.M., et al., *MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in Serum and Tissue: Potential Biomarkers in Sporadic Breast Cancer*. Frontiers in Genetics, 2022: p. 1414.
30. Robin, X., et al., *pROC: an open-source package for R and S+ to analyze and compare ROC curves*. BMC bioinformatics, 2011. **12**(1): p. 1-8.
31. Calvano Filho, C.M.C., et al., *Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p*. Tumor Biology, 2014. **35**(8): p. 7733-7741.
32. Jonsdottir, K., et al., *Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers*. PloS one, 2012. **7**(11): p. e48692.
33. Zhang, L., et al., *MicroRNA-224 promotes tumorigenesis through downregulation of caspase-9 in triple-negative breast cancer*. Disease markers, 2019. **2019**.
34. Huang, L., et al., *MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells*. Biochemical and biophysical research communications, 2012. **425**(2): p. 127-133.
35. Aakula, A., et al., *MicroRNA-135b regulates ER α , AR and HIF1AN and affects breast and prostate cancer cell growth*. Molecular oncology, 2015. **9**(7): p. 1287-1300.
36. Fisher, B., C.K. Redmond, and E.R. Fisher, *Evolution of knowledge related to breast cancer heterogeneity: a 25-year retrospective*. Journal of Clinical Oncology, 2008. **26**(13): p. 2068-2071.
37. Blenkiron, C., et al., *MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype*. Genome biology, 2007. **8**(10): p. 1-16.
38. Cizeron-Clairac, G., et al., *MiR-190b, the highest up-regulated miRNA in ER α -positive compared to ER α -negative breast tumors, a new biomarker in breast cancers? BMC cancer*, 2015. **15**(1): p. 1-14.

39. Joshi, T., et al., *Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer*. *Oncotarget*, 2016. **7**(35): p. 57239.
40. Dai, W., et al., *miR-148b-3p, miR-190b, and miR-429 regulate cell progression and act as potential biomarkers for breast cancer*. *Journal of breast cancer*, 2019. **22**(2): p. 219-236.
41. Ma, D., et al., *Circular RNA ABCB10 promotes non-small cell lung cancer progression by increasing E2F5 expression through sponging miR-584-5p*. *Cell Cycle*, 2020. **19**(13): p. 1611-1620.
42. Lee, S.B., et al., *Tumor suppressor miR-584-5p inhibits migration and invasion in smoking related non-small cell lung cancer cells by targeting YKT6*. *Cancers*, 2021. **13**(5): p. 1159.
43. Guo, T., et al., *miR-584-5p regulates migration and invasion in non-small cell lung cancer cell lines through regulation of MMP-14*. *Molecular Medicine Reports*, 2019. **19**(3): p. 1747-1752.
44. Eisenmann, K., et al., *5q-myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics*. *Oncogene*, 2009. **28**(39): p. 3429-3441.
45. Lehmann, S., et al., *Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice*. *Leukemia*, 2007. **21**(9): p. 1931-1936.
46. Ueno, K., et al., *Tumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma*. *British journal of cancer*, 2011. **104**(2): p. 308-315.
47. Cava, C., et al., *Theranostic application of miR-429 in HER2+ breast cancer*. *Theranostics*, 2020. **10**(1): p. 50.
48. He, Z., et al., *Up-regulation of MiR-452 inhibits metastasis of non-small cell lung cancer by regulating BM11*. *Cellular Physiology and Biochemistry*, 2015. **37**(1): p. 387-398.
49. Kristensen, H., et al., *Hypermethylation of the GABRE~ miR-452~ miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy*. *Clinical Cancer Research*, 2014. **20**(8): p. 2169-2181.
50. Liu, L., et al., *Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas*. *Clinical Cancer Research*, 2013. **19**(13): p. 3429-3438.
51. Li, W., et al., *Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A*. *Oncology Letters*, 2017. **14**(2): p. 2559-2565.
52. Cava, C., et al., *How interacting pathways are regulated by miRNAs in breast cancer subtypes*. *BMC bioinformatics*, 2016. **17**(12): p. 111-133.
53. Loke, S.Y., et al., *A circulating miRNA signature for stratification of breast lesions among women with abnormal screening mammograms*. *Cancers*, 2019. **11**(12): p. 1872.
54. Chang, N., et al., *Long Noncoding RNA LINC00857 Promotes Proliferation, Migration, and Invasion of Colorectal Cancer Cell through miR-1306/Vimentin Axis*. *Computational and Mathematical Methods in Medicine*, 2021. **2021**.


Supporting information captions:

Supplementary Fig. 1: The differential expression of miR-190b (A), miR-18a-5p (B), miR-505-3p (C), miR-224-5p (D), miR-577 (E), miR-135b-5p (F), miR-584-5p (G), miR-452-5p (H), miR-452-3p (I), and miR-1306-5p (J) in ER+ versus ER– breast tumor samples of TCGA.


Supplementary Fig. 2: A ROC curve for the combination of miR-190b, miR-18a-5p, miR-505-3p, miR-224-5p, miR-135b-5p, miR-584-5p, miR-452-5p, and miR-1306-5p in ER+ and ER– breast tumor samples of TCGA which created the AUC value of 0.977.

Supplementary Fig. 3: The expression of miR-190b, miR-584-5p, miR-452-5p, and miR-1306-5p (relative to u-48) in ER–/PR– and ER+/PR+ breast tumor samples. The results of the qRT-PCR analysis revealed that the measured expression level of miR-190b is lower in each 9 ER–/PR– samples (A) and is higher in each 8 ER+/PR+ samples (B), in comparison with the expression levels of the other three miRs in those samples (The expression of miR-452-5p was not detectable in T1, T2, T4, T8, T11, T12, T13, T14, T15, T16, and T17 samples).


A)




B)




C)




D)




A)




B)




C)




D)




A)




B)




C)




D)




A)




D)




B)



E)



C)



F)

